JP2024543911A - 細菌感染に対する治療薬として使用するための抗体 - Google Patents

細菌感染に対する治療薬として使用するための抗体 Download PDF

Info

Publication number
JP2024543911A
JP2024543911A JP2024531252A JP2024531252A JP2024543911A JP 2024543911 A JP2024543911 A JP 2024543911A JP 2024531252 A JP2024531252 A JP 2024531252A JP 2024531252 A JP2024531252 A JP 2024531252A JP 2024543911 A JP2024543911 A JP 2024543911A
Authority
JP
Japan
Prior art keywords
seq
antibody
sequence
domain comprises
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543911A5 (https=
Inventor
スティーヴン・リース
アイシャ・クリシュナ
シォバーン・オリアリ
ヨセフィン・バートホールドソン・スコット
サイモン・ワトソン
スティーヴン・ベイカー
Original Assignee
カイマブ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイマブ・リミテッド filed Critical カイマブ・リミテッド
Publication of JP2024543911A publication Critical patent/JP2024543911A/ja
Publication of JP2024543911A5 publication Critical patent/JP2024543911A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1218—Acinetobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024531252A 2021-11-26 2022-11-25 細菌感染に対する治療薬として使用するための抗体 Pending JP2024543911A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2117111.1 2021-11-26
GBGB2117111.1A GB202117111D0 (en) 2021-11-26 2021-11-26 Antibodies for use as therapeutics against bacterial infections
PCT/EP2022/083353 WO2023094628A1 (en) 2021-11-26 2022-11-25 Antibodies for use as therapeutics against bacterial infections

Publications (2)

Publication Number Publication Date
JP2024543911A true JP2024543911A (ja) 2024-11-26
JP2024543911A5 JP2024543911A5 (https=) 2025-12-03

Family

ID=80038446

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531252A Pending JP2024543911A (ja) 2021-11-26 2022-11-25 細菌感染に対する治療薬として使用するための抗体

Country Status (6)

Country Link
US (1) US20250026816A1 (https=)
EP (1) EP4436994A1 (https=)
JP (1) JP2024543911A (https=)
CN (1) CN118922440A (https=)
GB (1) GB202117111D0 (https=)
WO (1) WO2023094628A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121108335B (zh) * 2025-10-17 2026-03-27 广州医科大学附属第一医院（广州呼吸中心） 一种治疗溃疡性结肠炎的抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
CN112500489B (zh) * 2021-02-07 2021-05-04 天津一瑞生物科技股份有限公司 一种抗oxa-23型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用

Also Published As

Publication number Publication date
WO2023094628A1 (en) 2023-06-01
CN118922440A (zh) 2024-11-08
EP4436994A1 (en) 2024-10-02
GB202117111D0 (en) 2022-01-12
US20250026816A1 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
CN110214154B (zh) 抗cd47抗体及其用途
KR102536145B1 (ko) 항-pd-1 항체 및 이의 용도
CN109069620B (zh) 拮抗剂ccr7受体的人源化抗体
CN103747803B (zh) 抗axl抗体及其用途
WO2021180205A1 (zh) Pvrig结合蛋白及其医药用途
US12103962B2 (en) E. coli specific antibodies
WO2019091449A1 (zh) Cd96抗体、其抗原结合片段及医药用途
TW202043278A (zh) 結合ｐｄ－ｌ１和ｏｘ４０的雙特異性抗體
CN112424231B (zh) 抗pd-1抗体及其剂量和用途
WO2022135467A1 (zh) 抗b7-h3抗体及其用途
CN110615840A (zh) 全人源的抗lag-3抗体及其应用
US20250026816A1 (en) Antibodies for Use as Therapeutics Against Bacterial Infections
WO2022078490A1 (zh) 抗erbb3抗体或其抗原结合片段及其医药用途
TWI806870B (zh) 抗pd-1抗體及其用途
TW202302635A (zh) Ｉｌ－３８專一性抗體
CN120795162A (zh) 针对il-13和tslp的双特异性抗体及其用途
WO2023283211A2 (en) Cd21 antibodies and uses thereof
CN117677396A (zh) Il-38特异性抗体
TW202411252A (zh) 抗pd-1抗體及其用途
HK40047725B (en) Anti-pd-1 antibodies, dosages and uses thereof
HK40047725A (en) Anti-pd-1 antibodies, dosages and uses thereof
HK40013319B (en) Anti-cd47 antibody and use thereof
HK40016537A (en) Anti-pd-1 antibodies and uses thereof
HK40013319A (en) Anti-cd47 antibody and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260108